(1R,2R)-2-amino-N-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]cyclopentane-1-carboxamide | 1443512-83-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (1R,2R)-2-amino-N-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]cyclopentane-1-carboxamide
• CAS: 1443512-83-1
• 化学式: C₂₄H₃₆ClN₃O₃
• 分子量: 450.021
• InChiKey: NNHDILPNEWHAFE-FIXDAVPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  95.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol 在 盐酸 、 L-酒石酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 生成 (1R,2R)-2-amino-N-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]cyclopentane-1-carboxamide
  参考文献：
  名称：

  The discovery of BMS-457, a potent and selective CCR1 antagonist

  摘要：

  A series of compounds which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor. Issues of PXR activity, ion-channel potency, and poor metabolic stability were addressed by the addition of a hydroxyl group to an otherwise lipophilic area in the molecule resulting in the discovery of preclinical candidate BMS-457 for the treatment of rheumatoid arthritis. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.079

文献信息

• The discovery of BMS-457, a potent and selective CCR1 antagonist
  作者：Daniel S. Gardner、Joseph B. Santella、John V. Duncia、Percy H. Carter、T.G.Murali Dhar、Hong Wu、Weiwei Guo、Cullen Cavallaro、Katy Van Kirk、Melissa Yarde、Stephanie W. Briceno、R. Robert Grafstrom、Richard Liu、Sima R. Patel、Andrew J. Tebben、Dan Camac、Javed Khan、Andrew Watson、Guchen Yang、Anne Rose、William R. Foster、Mary Ellen Cvijic、Paul Davies、John Hynes

  DOI：10.1016/j.bmcl.2013.04.079

  日期：2013.7

  A series of compounds which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor. Issues of PXR activity, ion-channel potency, and poor metabolic stability were addressed by the addition of a hydroxyl group to an otherwise lipophilic area in the molecule resulting in the discovery of preclinical candidate BMS-457 for the treatment of rheumatoid arthritis. (c) 2013 Elsevier Ltd. All rights reserved.